Indian Journal of Pharmacy and Pharmacology


Cost analysis study of different brands of commonly used drugs for bronchial asthma available in india -A pharmacoeconomics study


Full Text PDF Share on Facebook Share on Twitter


Author Details: Dharani Devangi, Shashirekha C.H, Shruthi S L

Volume : 4

Issue : 4

Online ISSN : 2393-9087

Print ISSN : 2393-9079

Article First Page : 176

Article End Page : 183


Abstract

Introduction: To evaluate the price variation of various brands of antiasthmatic drugs available in single and in combination.
Materials and Methods: An observational study was carriedoutusing ‘CIMS’ &‘IDR’ (July-Oct 2016), where in the difference in the maximum and minimum price of a particular drug beingmanufactured by differentpharmaceutical companies, in the same strength, number and dosage formwas compared and the percentage variation in price was calculated. Data is analysed using descriptive statistical formula.
Results: In single drug therapy, among bronchodilator, β2 sympathomimetic: salbutamol (4mg) andsalbutamol (20µg) shows maximum and minimum price variation of 333.5% and1.47%. Among Leukotriene antagonists, montelukast (5mg tab) shows maximum of 185% and minimum of 0.539% as chewable tablet. Mast cell stabilizer ketotifen (1mg) shows maximum of 195.23% and minimum 142.307% as syrup. Among systemic corticosteroids methylprednisolone showed maximum and minimum of 701.01% and 4.16% 4mg and 2mg dosages. Inhalational steroids budesonide (0.5mg/ml) shows maximum of 486.5% and fluticasone propionate (50µg) shows minimum of 0.41%. In combination therapy salbutamol with theophylline shows a maximum of 900% and terbutaline, ambroxol hydrochloride with guaiphenesin shows minimum of 0.71% while Inhalational steroids maximum of 80.06% with fluticasone(100µg), formoterol fumarate(6µg) combination and minimum of 0.37% with budesonide(40µg) and formoterol fumarate(6µg).
Conclusion: The percentage price variation of different brands of the same drug and dosage manufactured in India for treatment of bronchial asthma is substantially wide. The pricing should be considered in view of better compliance. The clinicians should be aware of these price variations to reduce the economic burden of drug therapy.

 
Keywords: Cost analysis, Antiasthmatic drugs, Brands, Cost evaluation, Price variation